This is a late party for Silview.media’s first anniversary. We missed the date too, in the current turmoils. But we wanted to give you a special treat. There’s no happiness in this birthday, Covidiots stole it all, but there is a glimpse of hope, knowledge still gets through the censorship barrage and knowledge is freedom.
So many people noticed that China and the World Bank / IMF (read Rothschild Dynasty) subjects not only stopped poking each other, they seem to dance in sync. They’re not wrong, Kissinger has been working on this for over 50 years now and then Soros upped the game until the balance tilted in 2015, the year of the WB/IMF Summit (clan gathering) in Hong Kong.
UPDATE: Looks like we already have an answer to the question in the tile of the above video:
Don’t believe what we say, research what we say and make your own minds is our motto, and for the coming year we’ll make it more visible. But in this post it’s not us saying any of this stuff… In fact this write up is done.
Disclaimer: If something reeks of desperation, it’s definitely not Zucc and the Bidens, the best circus band on the planet
Right out of the flying bat that gave us Corona: It was me the beast who has committed all these unspeakable acts, I’m like Epstein on Viagra! Below you have all the evidence we collected from Fakebook, probably more to be revealed as elections approach. Notice that I even pimped Xi. Obey your new Pimp Lord!
AH, ALMOST FORGOT: DID FACEBOOK JUST IMPLY THERE’S SEXUAL ACTIVITY IN THAT PHOTO WITH JOE AND XI?
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Very interesting turn of events: Two nights ago got my hard-drive burnt as I was uploading a videowith Joe Biden being more Joe Biden than he’s ever been. So yesterday I got a new laptop and guess what I found on it? Some files from Hunter Biden’s lost laptop.
LATEST: Just about an hour ago, AN AUDIO RECORDING EXCLUSIVELY OBTAINED BY THE NATIONAL PULSE REVEALS HUNTER BIDEN DISCUSSING BUSINESS INVOLVEMENT WITH A “SPY CHIEF OF CHINA” AND HOW HIS BUSINESS PARTNER DEVON ARCHER NAMED HIM AND HIS FATHER AS WITNESSES IN A SOUTHERN DISTRICT OF NEW YORK CRIMINAL CASE.
And also this: Sept 24th: China whistle-blowers announce the Hunter Biden leaks and CCP take over of US. I will bring more light about the sources behind this soonish
As you can see below, Facebook has just confirmed we’re talking child exploitation here. And Facebook hires truth-checkers, so they must be the truth-overlords, right?
Update: Facebook also said our cover photo is breaching their child exploitation terms blah blah. As opposed to their countless thriving paedophile groups. However, in this case, the child seems to have been exploited before, at least for work:
I haven’t fvcked-checked this, but the word is some Chinese anti-communist dissidents got pissed at the Bidens for being owned by the CCP and they leaked these files below on Chinese websites. Waiting for Politifact and USA Today to cast some light on this situation.
Until then, I’ll be publishing these files shortly, here as I go trough them. here’s a couple of trailers for now. Some people will get upset that my HDD broke and I got this one instead.
This is an 100% genuine official quote we dug up from the man that was at the helms of Operation Paperclip, has been Nixon’s Assistant for National Security Affairs and it is said to be Trump’s shadow adviser. This is not even the juiciest detail in the document we obtained from University of Southern California.
Chinese leader Mao Zedong met republican US president Richard Nixon on February 21, 1972, that is no secret to anybody. However, the meeting took place in Chairman Mao’s living quarters and the precise details of the conversation have not been known until more recently, when they have been declassified and published by USC US-China Institute of the Southern California University. They didn’t draw any public attention, and I think they should.
Below we publish the integral declassified transcript of the Beijing meeting between China’s leader and America’s, as made public by SCU. Emphasis added by us on some paragraphs.
February 21, 1972
MEMORANDUM OF CONVERSATION
PARTICIPANTS: Chairman Mao Tsetung Prime Minister Chou En-lai Wang Hai-jung, Deputy Chief of Protocol of the Foreign Ministry Tang Wen-sheng, Interpreter
President Nixon Henry A. Kissinger, Assistant to the President for National Security Affairs Winston Lord, National Security Council Staff (Notetaker)
DATE AND TIME: Monday, February 21, 1972- 2:50-3:55 p.m.
PLACE: Chairman Mao’s Residence, Peking
(There were opening greetings during which the Chairman welcomed President Nixon, and the President expressed his great pleasure at meeting the Chairman.)
President Nixon: You read a great deal. The Prime Minister said that you read more than he does.
Chairman Mao: Yesterday in the airplane you put forward a very difficult problem for us. You said that what it is required to talk about are philosophic problems.
President Nixon: I said that because I have read the Chairman’s poems and speeches, and I know he was a professional philosopher. (Chinese laugh.)
Chairman Mao: (looking at Dr. Kissinger) He is a doctor of philosophy?
President Nixon: He is a doctor of brains.
Chairman Mao: What about asking him to be the main speaker today?
President Nixon: He is an expert in philosophy.
Dr. Kissinger: I used to assign the Chairman’s collective writings to my classes at Harvard.
Chairman Mao: Those writings of mine aren’t anything. There is nothing instructive in what I wrote.
(Looking toward the photographers) Now they are trying to interrupt our meeting, our order here.
President Nixon: The Chairman’s writings moved a nation and have changed the world.
Chairman Mao: I haven’t been able to change it. I’ve only been able to change a few places in the vicinity of Peking.
Our common old friend, Generalissimo Chiang Kai-shek, doesn’t approve of this. He calls us communist bandits. He recently issued a speech. Have you seen it?
President Nixon: Chiang Kai-shek calls the Chairman a bandit. What does the Chairman call Chiang Kai-shek?
Prime Minister Chou: Generally speaking we call them Chiang Kai-shek’s clique. In the newspapers sometimes we call him a bandit; we are also called bandits in turn. Anyway, we abuse each other.
Chairman Mao: Actually, the history of our friendship with him is much longer than the history of your friendship with him.
President Nixon: Yes, I know.
Chairman Mao: We two must not monopolize the whole show. It won’t do if we don’t let Dr. Kissinger have a say.
Chairman Mao to Dr. Kissinger: You have been famous about your trips to China.
Dr. Kissinger: It was the President who set the direction and worked out the plan.
President Nixon: He is a very wise assistant to say it that way. (Mao and Chou laugh.)
Chairman Mao: He is praising you, saying you are clever in doing so.
President Nixon: He [Kissinger] doesn’t look like a secret agent. He is the only man in captivity who could go to Paris 12 times and Peking once and no one knew it, except possibly a couple of pretty girls.
Dr. Kissinger: They didn’t know it; I used it as a cover.
Chairman Mao: In Paris?
President Nixon: Anyone who uses pretty girls as a cover must be the greatest diplomat of all time.
Chairman Mao: So your girls are very often made use of?
President Nixon: His girls, not mine. It would get me into great trouble if I used girls as a cover.
Prime Minister Chou: (laughs) Especially during elections. (Kissinger laughs.) Dr. Kissinger doesn’t run for President because he wasn’t born a citizen of the United States.
Dr. Kissinger: Miss Tang is eligible to be President of the United States.
President Nixon: She would be the first woman President. There’s our candidate.
Chairman Mao: It would be very dangerous if you have such a candidate. But let us speak the truth. As for the Democratic Party, if they come into office again, we cannot avoid contacting them.
President Nixon: We understand. We will hope that we don’t give you that problem.
Chairman Mao: Those questions are not questions to be discussed in my place. They should be discussed with the Premier. I discuss the philosophical questions. That is to say, I voted for you during your election. There is an American here called Mr. Frank Coe, and he wrote an article precisely at the time when your country was in havoc, during your last electoral campaign. He said you were going to be elected President. I appreciated that article very much. But now he is against the visit.
President Nixon: When the President says he voted for me, he voted for the lesser of two evils.
Chairman Mao: I like rightists. People say you are rightists, that the Republican Party is to the right, that Prime Minister Heath is also to the right. President Nixon: And General DeGaulle. Chairman Mao: DeGaulle is a different question. They also say the Christian Democratic Party of West Germany is also to the right. I am comparatively happy when these people on the right come into power.
President Nixon: I think the important thing to note is that in America, at least at this time, those on the right can do what those on the left talk about.
Dr. Kissinger: There is another point, Mr. President. Those on the left are pro-Soviet and would not encourage a move toward the People’s Republic, and in fact criticize you on those grounds.
Chairman Mao: Exactly that. Some are opposing you. In our country also there is a reactionary group which is opposed to our contact with you. The result was that they got on an airplane and fled abroad.
Prime Minister Chou: Maybe you know this.
Chairman Mao: Throughout the whole world, the U.S. intelligence reports are comparatively accurate. The next was Japan. As for the Soviet Union, they finally went to dig out the corpses, but they didn’t say anything about it.
Prime Minister Chou: In Outer Mongolia.
President Nixon: We had similar problems recently in the crisis on India-Pakistan. The American left criticized me very heavily for failing to side with India. This was for two reasons: they were pro-Indian and they were pro-Soviet.
I thought it was important to look at the bigger issue. We could not let a country, no matter how big, gobble up its neighbor. It cost – I don’t say this with sorrow because it was right – it cost me politically, but I think history will record that it was the right thing to do.
Chairman Mao: As a suggestion, may I suggest that you do a little less briefing? (The President points at Dr. Kissinger and Chou laughs.) Do you think it is good if you brief others on what we talk about, our philosophic discussions here?
President Nixon: The Chairman can be sure that whatever we discuss, or whatever I and the Prime Minister discuss, nothing goes beyond the room. That is the only way to have conversations at the highest level.
Chairman Mao: That’s good.
President Nixon: For example, I hope to talk with the Prime Minister and later with the Chairman about issues like Taiwan, Vietnam and Korea. I also want to talk about—and this is very sensitive—the future of Japan, the future of the subcontinent, and what India’s role with be; and on the broader world scene, the future of US-Soviet relations. Because only if we see the whole picture of the world and the great forces that move the world will we be able to make the right decisions about the immediate and urgent problems that always completely dominate our vision.
Chairman Mao: All those troublesome problems I don’t want to get into very much. I think your topic is better—philosophic questions.
President Nixon: For example, Mr. Chairman, it is interesting to note that most nations would approve of this meeting, but the Soviets disapprove, the Japanese have doubts which they express, and the Indians disapprove. So we must examine why, and determine how our policies should develop to deal with the whole world, as well as the immediate problems such as Korea, Vietnam, and of course, Taiwan.
Chairman Mao: Yes, I agree.
President Nixon: We, for example, must ask ourselves—again in the confines of this room—why the Soviets have more forces on the border facing you than on the border facing Western Europe. We must ask ourselves, what is the future of Japan? Is it better—here I know we have disagreements—is it better for Japan to be neutral, totally defenseless, or it is [sic] better for a time for Japan to have some relations with the United States? The point being—I am talking now in the realm of philosophy—in international relations there are no good choices. One thing is sure—we can leave no vacuums, because they can be filled. The Prime Minister, for example, has pointed out that the United States reaches out its hands and that the Soviet Union reaches out its hands. The question is which danger the People’s Republic faces, whether it is the danger of American aggression or Soviet aggression. There are hard questions, but we have to discuss them.
Chairman Mao: At the present time, the question of aggression from the United States or aggression from China is relatively small; that is, it could be said that this is not a major issue, because the present situation is one in which a state of war does not exist between our two countries. You want to withdraw some of your troops back on your soil; ours do not go abroad.
Therefore, the situation between our two countries is strange because during the past 22 years our ideas have never met in talks. Now the time is less than 10 months since we began playing table tennis; if one counts the time since you put forward your suggestion at Warsaw it is less than two years. Our side also is bureaucratic in dealing with matters. For example, you wanted some exchange of persons of a personal level, things like that; also trade. But rather than deciding that we stuck with our stand that without settling major issues there is nothing to do with smaller issues. I myself persisted in that position. Later on I saw you were right, and we played table tennis. The Prime Minister said this was also after President Nixon came to office.
The former President of Pakistan introduced President Nixon to us. At that time, our Ambassador to Pakistan refused to agree on our having a contact with you. He said it should be compared whether President Johnson or President Nixon would be better. But President Yahya said the two men cannot be compared, that these two men are incomparable. He said that one was like a gangster—he meant President Johnson. I don’t know how he got that impression. We on our side were not very happy with that President either. We were not very happy with your former Presidents, beginning from Truman through Johnson. We were not very happy with these Presidents, Truman and Johnson. In between there were eight years of a Republican President. During that period probably you hadn’t thought things out either.
Prime Minister Chou: The main thing was John Foster Dulles’ policy.
Chairman Mao: He (Chou) also discussed this with Dr. Kissinger before.
President Nixon: But they (gesturing towards Prime Minister Chou and Dr. Kissinger) shook hands. (Chou laughs.)
Chairman Mao: Do you have anything to say, Doctor?
Dr. Kissinger: Mr. Chairman, the world situation has also changed dramatically during that period. We’ve had to learn a great deal. We thought all socialist/communist states were the same phenomenon. We didn’t understand until the President came into office the different nature of revolution in China and the way revolution had developed in other socialist states.
President Nixon: Mr. Chairman, I am aware of the fact that over a period of years my position with regard to the People’s Republic was one that the Chairman and Prime Minister totally disagreed with. What brings us together is a recognition of a new situation in the world and a recognition on our part that what is important is not a nation’s internal political philosophy. What is important is its policy toward the rest of the world and toward us. That is why—this point I think can be said to be honest—we have differences. The Prime Minister and Dr. Kissinger discussed these differences.
It also should be said—looking at the two great powers, the United States and China—we know China doesn’t threaten the territory of the United States; I think you know the United States has no territorial designs on China. We know China doesn’t want to dominate the United States. We believe you too realize the United States doesn’t want to dominate the world. Also—maybe you don’t believe this, but I do—neither China nor the United States, both great nations, want to dominate the world. Because our attitudes are the same on these two issues, we don’t threaten each others’ territories.
President Nixon: Therefore, we can find common ground, despite our differences, to build a world structure in which both can be safe to develop in our own way on our own roads. That cannot be said about some other nations in the world.
Chairman Mao: Neither do we threaten Japan or South Korea.
President Nixon: Nor any country. Nor do we.
Chairman Mao: (Checking the time with Chou) Do you think we have covered enough today?
President Nixon: Yes. I would like to say as we finish, Mr. Chairman, we know you and the Prime Minister have taken great risks in inviting us here. For us also it was a difficult decision. But having read some of the Chairman’s statements, I know he is one who sees when an opportunity comes, that you must seize the hour and seize the day.
I would also like to say in a personal sense –and this to you Mr. Prime Minister—you do not know me. Since you do not know me, you shouldn’t trust me. You will find I never say something I cannot do. And I always will do more than I can say. On this basis I want to have frank talks with the Chairman and, of course, with the Prime Minister.
Chairman Mao: (Pointing to Dr. Kissinger) “Seize the hour and seize the day.” I think that, generally speaking, people like me sound a lot of big cannons. (Chou laughs) That is, things like “the whole world should unite and defeat imperialism, revisionism, and all reactionaries, and establish socialism.”
President Nixon: Like me. And bandits.
Chairman Mao: But perhaps you as an individual may not be among those to be overthrown. They say that he (Dr. Kissinger) is also among those not to be overthrown personally. And if all of you are overthrown we wouldn’t have any more friends left.
President Nixon: Mr. Chairman, the Chairman’s life is well-known to all of us. He came from a very poor family to the top of the most populous nation in the world, a great nation. My background is not so well known. I also came from a very poor family, and to the top of a very great nation. History has brought us together. The question is whether we, with different philosophies, but both with feet on the ground, and having come from the people, can make a breakthrough that will serve not just China and America, but the whole world in the years ahead. And that is why we are here.
Chairman Mao: Your book, “The Six Crises,” is not a bad book.
President Nixon: He (Mao) reads too much.
Chairman Mao: Too little. I don’t know much about the United States. I must ask you to send some teachers here, mainly teachers of history and geography.
President Nixon: That’s good, the best.
Chairman Mao: That’s what I said to Mr. Edgar Snow, the correspondent who passed away a few days ago.
President Nixon: That was very sad.
Chairman Mao: Yes, indeed.
It is alright to talk well and also alright if there are no agreements, because what use is there if we stand in deadlock? Why is it that we must be able to reach results? People will say… if we fail the first time, then people will talk why are we not able to succeed the first time? The only reason would be that we have taken the wrong road. What will they say if we succeed the second time?
(There were then some closing pleasantries. The Chairman said he was not well. President Nixon responded that he looked good. The Chairman said that appearances were deceiving. After handshakes and more pictures, Prime Minister Chou then escorted the President out of the residence.)
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
In 2013, the Chinese authorities branded the international pharma giant GSK a “criminal godfather”, accusing it of running a £320m slush fund to bribe doctors and hospital officials with cash payments and visits to prostitutes. – The Guardian American public couldn’t care much, but those events built up to Moncef Slaoui‘s nomination as Trump’s “vaccine czar”
If corruption was a company, it would be GlaxoSmithKline (GSK) with “Trump’s new vaccine czar”, Moncef Slaoui, at the helms of Research and Vaccines departments. It all peaked in 2010-2015 with some of the most sordid scandals people have ever ignored. Many will pay attention now, when things escalated to truly painful levels.
GlaxoSmithKline (GSK) can trace its roots back to a small apothecary in 18th Century London. Through multiple corporate mergers, GSK found its current form in 2001. It is well-known for its asthma inhalers like Advair and Breo. They have been constantly embroidered in scandals long before 2001. Suffice for now to mention a case of actual officially-recorded conspiracy, as reported by New York Times: In 1996 SmithKline Beecham was one of 15 drug companies that together agreed to pay more than $408 million to settle a class action lawsuit charging them with conspiring to fix prices they charged to thousands of independent pharmacies. In addition to contributing $30 million to the financial settlement, SmithKline agreed to supply the plaintiffs with a quantity of the generic version of its Tagamet ulcer medication worth $20 million.
We’re not going to review every GSK case in this investigation, just the truly spectacular and relevant ones from the more recent times, when the Research & Development and Vaccines departments were under Moncef Slaoui’s command. A new name to most, the Moroccan scientist has been dubbed by US media “Trump’s vaccine czar”, a few days back, when the US president made him co-chief of Operation Warp Speed, the coronavirus mass-vaccination campaign about to start in US.
GSK has began to break records with its penalties and settlements in 2006, when it promised “it would pay $3.1 billion to the U.S. Internal Revenue Service to resolve a 17-year dispute over the tax treatment of transactions between the company’s U.S. operation and the parent company. The settlement, the largest in IRS history, focused on the issue of transfer pricing—a method by which transnational corporations artificially reduce their tax liabilities”, as New York TImes reported
Anthony Faucci, Trump’s Vaccine Czar Moncef Slaoui and WHO collaborated on the H1N1 scamdemic of 2009, a rehearsal for the Plandemic of 2020. Their vaccine destroyed thousands of children
“As chief of vaccines at GSK, Slaoui oversaw the development of the disastrous Pandemrix vaccine for swine flu, a shot that was rushed to market without proper testing in the midst of a 2009 epidemic, during which public health officials were shrieking about enormous death tolls that never materialized, with some claiming the death toll would rival the 1918 influenza pandemic (sound familiar?).” RT reported recently in a quite superficial review of the H1N1 scandal of 2009. Let me give you the full picture.
A couple of recent articles by Prof Michel Chossudovsky for Global Research make a great review of the H1N1 2009 scamdemic, greatly completing my work. Chossudovsky practices practices the same old-school document-based style of journalism I was trained too, so I will copiously quote his work in this chapter, with regards and acknowledgements :
Based on incomplete and scanty data, the WHO Director General nonetheless predicted with authority that: “as many as 2 billion people could become infected over the next two years — nearly one-third of the world population.” (World Health Organization as reported by the Western media, July 2009).
It was a multibillion bonanza for Big Pharma supported by the WHO’s Director-General Margaret Chan,(wife of a high Chinese government official – Silview’s note).
In June 2009, Margaret Chan made the following statement:
Millions of doses of swine flu vaccine had been ordered by national governments from Big Pharma. Millions of vaccine doses were subsequently destroyed: a financial bonanza for Big Pharma, an expenditure crisis for national governments.(Global Research)
The media went immediately into high gear (without a shred of evidence). Fear and Uncertainty. Public opinion was deliberately misled
“Swine flu could strike up to 40 percent of Americans over the next two years and as many as several hundred thousand could die if a vaccine campaign and other measures aren’t successful.” (Official Statement of Obama Administration, Associated Press, 24 July 2009).
“The U.S. expects to have 160 million doses of swine flu vaccine available sometime in October”, (Associated Press, 23 July 2009)
Wealthier countries such as the U.S. and Britain will pay just under $10 per dose [of the H1N1 flu vaccine]. … Developing countries will pay a lower price.” [circa $40 billion for Big Pharma?] (Business Week, July 2009)
What was most governments’ vaccine of choice? Pandemrix, elaborated by Moncef Slaoui and GlaxoSmithKline
But the H1N1 pandemic never happened. There was no pandemic affecting 2 billion people…
The H1N1 scamdemic was endorsed in US by the CDC and the NIAID headed by Dr. Anthony Fauci. NIAID Director Fauci also endorsed Moncef Slaoui’s Pandemrix vaccine, which turned out to be a multi-billion dollar life-ruining scam:
The Pandemrix vaccine made by GlaxoSmithKline (GSK) was given to 6 million people in Britain and millions more across Europe during the 2009-10 swine flu pandemic, but was withdrawn when doctors noticed a rise in narcolepsy cases among those who received the jab.
Narcolepsy is a permanent condition that can cause people to fall asleep dozens of times a day, even when they are in mid-conversation. Some suffer from night terrors and a problem with muscular control called cataplexy that can lead them to collapse on the spot. (Guardian, September 25, 2015)
In UK, the result of the hasty approval process was an unsafe, ineffective shot that left over a thousand recipients permanently brain-damaged, some 80 percent of them children. Forty percent of NHS staffers were vaccinated under false pretenses, told the shot was safe and effective. The UK government was forced to pay out millions of pounds in compensation, as GSK had refused to supply the drug to governments until it was indemnified against lawsuits.
“The Pandemrix vaccine, made by GlaxoSmithKline, was given to high-risk groups, including children and those with asthma, diabetes and heart disease at the height of the 2009-10 swine flu pandemic. Across Europe, around 31 million people received the jab. The vaccine was made specifically to tackle pandemics and is very different to the normal seasonal flu vaccine which has not been linked to narcolepsy.
The condition is a rare but serious neurological disorder that affects about 31,000 people in Britain. The condition can cause massive sleep disruption. The worst hit are often young people who face enormous learning difficulties at school and university. The disorder can destroy self-esteem, and bullying is common. Adults can lose their jobs, their driving licences, and can have difficulties with relationships. Some narcoleptics have another condition called cataplexy, a total loss of muscle control.” – The Guardian 2013
In June, a 12-year-old boy was awarded £120,000 by a court that ruled he had been left severely disabled by narcolepsy caused by Pandemrix. The win ended a three-year battle with the government that argued his illness was not serious enough to warrant compensation.
The increased risk of narcolepsy after vaccination with ASO3 adjuvanted pandemic A/H1N1 2009 vaccine indicates a causal association, consistent with findings from Finland. – British Medical Journal
A Department of Health spokesperson said: “Pandemrix was developed specifically for use in a flu pandemic when the number of lives lost and serious cases could have been enormous.” “The decision to recommend that children got this vaccine during the flu pandemic was based on evidence available at the time, along with the advice from the European Medicines Agency which approved its use.
The government is expected to receive a bill of approximately £60 million, with each of the 60 victims expected to receive about £1 million each.
Peter Todd, a lawyer who represented many of the claimants, told the Sunday Times: “There has never been a case like this before. The victims of this vaccine have an incurable and lifelong condition and will require extensive medication.”
Following the swine flu outbreak of 2009, about 60 million people, most of them children, received the vaccine.
It was subsequently revealed that the vaccine, Pandemrix, can cause narcolepsy and cataplexy in about one in 16,000 people, and many more are expected to come forward with the symptoms.
Across Europe, more than 800 children are so far known to have been made ill by the vaccine.
In a bitter irony, it was the UK Government (rather than GSK) that paid for the Vaccine Brain Damages in Children.
But the Brain Damage impacts documented in the UK and EU was but the tip of the iceberg.
Thousands of people got sick from the H1N1 Vaccine (reported and unreported cases).
GSK’s ArepanrixTD applied in Canada
The WHO’s H1N1 pandemic was declared in June 11, 2009. GSK was on contract to the Canadian government. The GSK’s ArepandrixTM vaccine was delivered to Canadian health authorities within less than four months.
Within four months?. Does that give them Time to Test????
Lots of people in Canada fell sick after receiving the H1N1 ArepanrixTD vaccine.
And that vaccine killed a little girl called Amina Abu, which then led to a ten year lawsuit against GSK.
A vaccine was rushed to market, and the five year old was among millions of Canadians to get the shot, amid widespread fears about the new pathogen.
Five days later, Amina’s older brother found her lying unconscious in the bathroom of the family’s east-end Toronto home. She was dead.
Her devastated parents came to blame the flu shot itself and sued the vaccine’s manufacturer, Glaxo Smith Kline (GSK), for $4.2 million. The little-noticed trial of that lawsuit drew toward a close on Tuesday, a rare judicial airing in Canada of a vaccine’s alleged side effects.
The parents’ lawyer, Jasmine Ghosn, alleged the preventive drug was brought out quickly and without proper testing during a chaotic flu season, as the federal government exerted “intense pressure” on Canadians to get immunized. (National Post, November 2019)
It took ten years for a judgment. The Family lost. GSK declined responsibility for her death. And the Canadian government reimbursed GSK’s legal expenses.
That lawsuit against GSK should be reopened. Canada’s government bears the burden of responsibility.
ArepanrixTD (2009) vs PandemrixTM (2009)
GSK has casually acknowledged that the ArepanrixTD which was used in Canada is “similar” to the GSK’s PandemrixTM applied in the UK and the EU, which led to brain damage in Children. It was subsequently withdrawn. But ArepandrixTD applied in Canada prevailed. An ArepandrixTD (2010) was subsequently released the following year (and compared to PandemrixTD (2009)
GSK acknowledges that PandemrixTD (2009) causes narcolepsy, which is categorized as “a chronic neurological disorder that affects the brain’s ability to control sleep-wake cycles.”
3. To date, how many people/children in Canada have reported developing narcolepsy after getting vaccinated with Arepanrix? What provinces do they reside in Canada?
GSK reports all cases of adverse events which the company is aware of in accordance with national and regional regulations. We respectfully defer to the Public Health Agency of Canada to address this question in more detail.
4. We read that there is currently a Canadian study sponsored by GSK to assess the risk of occurrence of narcolepsy following the administration of Arepanrix – Why did you sponsor that study? When will the results of that study be published?
We are currently supporting a study that is being conducted in Quebec where Arepanrix™ (H1N1) was used. Further research is needed to evaluate the potential association between GSK`s adjuvanted H1N1 pandemic flu vaccine and narcolepsy in a country where a similar vaccine to Pandemrix™ (H1N1) was used, and where a more robust assessment of the potential association could be conducted, using a design aimed at limiting the impact of biases. The preliminary results of this study are anticipated to be published by early 2014.
There was no investigation into who was behind this multibillion fraud. Several critics said that the H1N1 Pandemic was “Fake”
The Parliamentary Assembly of the Council of Europe (PACE), a human rights watchdog, is publicly investigating the WHO’s motives in declaring a pandemic. Indeed, the chairman of its influential health committee, epidemiologist Wolfgang Wodarg, has declared that the “false pandemic” is “one of the greatest medicine scandals of the century.” (Forbes, February 10, 2010)
The World Health Organization’s handling of the swine flu pandemic was deeply marred by secrecy and conflict of interest with drug companies, a top medical journal said Friday.
The British Medical Journal, or BMJ, found that WHO guidelines on the use of antiviral drugs were prepared by experts who had received consulting fees from the top two manufacturers of these drugs, Roche and GlaxoSmithKline, or GSK.
In apparent violation of its own rules, the WHO did not publicly disclose these conflicts when the guidelines were drawn up in 2004, according to the report, jointly authored by the London-based non-profit Bureau of Investigative Journalism.
The WHO’s advice led governments worldwide to stockpile vast quantities of antivirals, and its decision to declare a pandemic in June 2009 triggered the purchase of billions of dollars worth of hastily manufactured vaccines.
Much of these stocks have gone unused because the pandemic turned out to be far less lethal than some experts feared, fueling suspicion that Big Pharma exerted undue influence on WHO decisions.
The report also reveals that at least one expert on the secret, 16-member “emergency committee” formed last year to advise the WHO on whether and when to declare a pandemic received payment during 2009 from GSK.
Announcing that swine flu had become a global pandemic automatically triggered latent contracts for vaccine manufacture with half-a-dozen major pharmaceutical companies, including GSK. The WHO has refused to identify committee members, arguing that they must be shielded from industry pressure. “The WHO’s credibility has been badly damaged,” BMJ editor Fiona Godlee said in an editorial.
In 2010, after 8 years of legal battles, it’s sentenced to pay $96 to a whistle-blower. who exposed serious contamination problems at GlaxoSmithKline’s (GSK) pharmaceutical manufacturing operations.
“Cheryl Eckard’s payment is thought to be the biggest ever handed to a US whistleblower. It was awarded after an eight-year fight, which ended yesterday, when GSK agreed to pay the US government $750m to settle civil and criminal charges that it manufactured and sold adulterated drug products.” – The Guardian
One may argue the cases above may speak volumes about GSK, but this not Slaoui’s department, he probably had nothing to do with it. Yes, he may have not had his own hands in these particular scandal, but wait for it, as you will see, corruption is the norm at GSK, not something you can easily overlook, so unless he was forced to work for this corruption galore, he was an accomplice, at least ethically and morally, as all his colleagues are. We get to Slaoui’s departments shortly.
Year 2012 finds GSK experimenting on Argentina’s poorest babies. Moncef Slaoui’s people were going to Argentina’s most disparaged areas, tracking and tricking the poorest and most illiterate people to allow vaccine trials on their kids and babies. 14 deaths ensued. “The firm failed to get proper consent from the children’s parents before injecting Synflorix, one of its bestselling vaccines, according to a judge in Buenos Aires. GSK was also criticised for keeping inadequate records of the children’s ages, medical histories and previous jabs. Evidence from Argentina’s medical regulator said that, in a few cases, scientists working for GSK relied on permission from under-age parents or illiterate grandparents, The Times reported. GSK and two of the scientists who led the trial have been fined a total of one million pesos (£150,000). Jorge Yabkowsky, president of the Argentine Federation of Health Professionals, told The Times: “These are people who depend entirely on the state apparatus and who are most often illiterate.” – The Telegraph
“The Argentinian Federation of Health Professionals accuses drug maker GlaxoSmithKline of misleading participants and pressuring poor families into joining a trial for the Synflorix vaccine, which the company says protects against bacterial pneumonia and meningitis.”They recruited children in an irregular manner. … They did not do what they were supposed to. They did not inform. There were not independent witnesses. They pressured the mothers of poor children,” said Jorge Yabkowsky, the federation’s director.” – CNN
The trial, known as Compas, involved 15,000 Argentine babies and 9,000 in Colombia and Panama. It started five years before this scandal and continued long after, despite the fine, because that’s just “cost of business” on Planet Pharma.
But that was peanuts to GSK’s budget. considering same year, 2012, they paid a $3bn (£1.8bn) fine for misselling drugs in the US, “Largest Health Care Fraud Settlement in U.S. History” in the words of US Department of Justice. DOJ further stated: <<GSK agreed to plead guilty to a three-count criminal information, including two counts of introducing misbranded drugs, Paxil and Wellbutrin, into interstate commerce and one count of failing to report safety data about the drug Avandia to the Food and Drug Administration (FDA). Under the terms of the plea agreement, GSK will pay a total of $1 billion, including a criminal fine of $956,814,400 and forfeiture in the amount of $43,185,600. The criminal plea agreement also includes certain non-monetary compliance commitments and certifications by GSK’s U.S. president and board of directors. GSK’s guilty plea and sentence is not final until accepted by the U.S. District Court.
GSK will also pay $2 billion to resolve its civil liabilities with the federal government under the False Claims Act, as well as the states. The civil settlement resolves claims relating to Paxil, Wellbutrin and Avandia, as well as additional drugs, and also resolves pricing fraud allegations.
“Today’s multi-billion dollar settlement is unprecedented in both size and scope. It underscores the Administration’s firm commitment to protecting the American people and holding accountable those who commit health care fraud,” said James M. Cole, Deputy Attorney General. “At every level, we are determined to stop practices that jeopardize patients’ health, harm taxpayers, and violate the public trust – and this historic action is a clear warning to any company that chooses to break the law.”>>
Rewind that: A Deputy Attorney General said in a DOJ press release that GSK “jeopardized patients’ health, harmed taxpayers, and violated the public trust“.
You think that’s bad? Reading further in the DOJ press release we find out that Bill Corr, Deputy Secretary of the Department of Health and Human Services (HHS) really called it out:
“cheaters who thought they could make an easy profit at the expense of public safety, taxpayers, and the millions of Americans who depend on programs like Medicare and Medicaid”
“GSK, one of the world’s largest healthcare and pharmaceuticals companies, admitted to promoting antidepressants Paxil and Wellbutrin for unapproved uses, including treatment of children and adolescents. The illegal practice is known as off-label marketing. The company also conceded charges that it held back data and made unsupported safety claims over its diabetes drug Avandia. It agreed to resolve civil liability for promoting asthma drug Advair and two lesser-known drugs for unapproved uses.
In addition, GSK has been found guilty of paying kickbacks to doctors.” – BBC
“The sales force bribed physicians to prescribe GSK products using every imaginable form of high-priced entertainment, from Hawaiian vacations [and] paying doctors millions of dollars to go on speaking tours, to tickets to Madonna concerts”
The public hardly got scandalized and mostly by the bribes, but the most serious crime is the one committed by Slaoui’s department, Forbes being one of the very few media that nailed this: “Keeping safety data secret: Federal investigators say that between 2001 and 2007, GlaxoSmithKline failed to disclose safety data from certain studies of Avandia to the Food and Drug Administration. This is, ethically, perhaps the most serious of the charges. Glaxo’s handling of the Avandia matter was fraught with bad disclosure bordering on deceit. During that time period, Avandia became the best-selling diabetes drug in the world. Now it not only bears warnings that it might cause heart attacks, its use has been so restricted that the drug has nearly vanished off Glaxo’s ledgers. To the extent that Glaxo kept Avandia’s heart risk from being recognized, that means that patients were exposed to added risks. For this, Glaxo is paying a fine of $243 million.”
As part of the settlement, GSK agreed to be monitored by US government officials for five years. Only to see the company embroiled in another humongous scandal within a year, as they re-based their corruption in China.
The 2013 scandal “started with sex tapes of the company’s China head, Mark Reilly and his Chinese girlfriend at a Shanghai department, which were sent to several senior executives of the company. The company’s investigations into the sex tapes made the paid investigator Peter Humphrey and his wife Yu Yingzeng in jail in China due to their breach of privacy law. With the bribery scandal made public by the Chinese police since June 2013, GSK had to admit its pervasive corruption in China. After tried in Changsha in September 2014, the company apologized to the Chinese people, and paid one of the biggest fines in Chinese history worth ¥3bn (£300m; €350m; $490m).4 executives of the company, including Mark Reilly, the only foreign citizens involved, were sentenced to jail. Reilly was deported from China as well. The sequent US Securities and Exchange Commission investigation was settled by GSK with a $20 million civil penalty in 2016, yet the UK Serious Fraud Office failed to finish the expensive investigation which was officially ended in 2019.” Wikipedia
The corruption at GSK was multi-levelled and ubiquitous, it wasn’t just bribes for sales, that’s why the scandal needed about 5 years to find closure, more or less. GSK board received an email in January 2013 where how China’s branch committed fraud in its operations was detailedly described in 5,200 words. The email was well written in English. The email said that GSK China disguised tourist travel in the disguise of international academic meetings. The company paid for the airline tickets and hotel rooms for such meetings to bribe Chinese medical professionals. The email continued by accusing GSK China of falsifying its books and records to illegally market drugs in China. The whistleblower made examples by the drug Lamictal, which was approved in China only for treating epilepsy, but was marketed as a drug for bipolar disorder aggressively. The drug killed a patient due to false marketing, but GSK chose to pay around 9,000 US dollars to silence the patient.
From 2013’s ScienceMag we find out that “accusations of data fabrication at GlaxoSmithKline’s China research site are quite real. That’s what we get from the latest developments in the case, as reported by BioCentury, Pharmalot, and the news section at Nature Medicine. Jingwu Zang, lead author on the disputed paper and former head of the Shanghai research site, has been dismissed from the company. Other employees are on administrative leave while an investigation proceeds, and GSK has said it has begun the process of retracting the paper itself. As for what’s wrong with the paper in question, BioCentury Extra has this:
GSK said data in a paper published in January 2010 in Nature Medicine on the role of interleukin-7 (IL-7) in autoimmune disease characterized data as the results of experiments conducted with blood cells of multiple sclerosis (MS) patients “when, in fact, the data reported were either the results of experiments conducted at R&D China with normal (healthy donor) samples or cannot be documented at all, suggesting that they well may have been fabricated.”
The pharmaceutical giant’s head of global research & development at the time, Moncef Slaoui, received a total remuneration package of $8.4m for his work in 2013, up from $6.6m in 2012.“
Moncef Slaoui was very close to the Chinese GSK division because, as I pointed out in my previous article, in 2007, he announced plans to establish a neurosciences research group in Shanghai that would employ a thousand scientists and cost $100 million. This was one of his biggest projects at GSK, so much of his time and energy were spent through at the China branch. Slaoui’s megalomaniac plans failed miserably and ceased operations in August 2017, which is the most probable cause of his departure from GSK same year.
The following year, 2014, “the pay packets of finance boss Simon Dingemans and vaccines head Moncef Slaoui also took a hit last year. Mr Dingemans received £1.9m, down from £3.3m the year before. Dr Slaoui got $4.3m (£2.8m), compared with his $8.4m remuneration in 2013.”, reported The Telegraph. GSK had to recover from one of the biggest fines in history!
“China has fined UK pharmaceuticals firm GlaxoSmithKline $490m (£297m) after a court found it guilty of bribery” – BBC, 2014
<<The record penalty follows allegations the drug giant paid out bribes to doctors and hospitals in order to have their products promoted. The court gave GSK’s former head of Chinese operations, Mark Reilly, a suspended three-year prison sentence and he is set to be deported. Other GSK executives have also been given suspended jail sentences.
Chinese authorities first announced they were investigating GSK in July last year (2013 – the year Slaoui was cashing big bonuses – Silview’s note), in what has become the biggest corruption scandal to hit a foreign firm in years. The company was accused of having made an estimated $150m in illegal profits.
GSK said it had “published a statement of apology to the Chinese government and its people”.
“Reaching a conclusion in the investigation of our Chinese business is important, but this has been a deeply disappointing matter for GSK,” said chief executive Sir Andrew Witty in a statement. “We have and will continue to learn from this. GSK has been in China for close to a hundred years and we remain fully committed to the country and its people,” he said. “We will also continue to invest directly in the country to support the government’s health care reform agenda and long-term plans for economic growth.”
Mick Cooper, analyst at Edison Investment Research in London, said: “GlaxoSmithKline will hope that this will draw a line under events in China, but it will take time for its Chinese commercial operations to recover.>> – BBC, 2014
US authorities then investigated whether GSK breached the Foreign Corrupt Practices Act, while the UK’s Serious Fraud Office (SFO) launched a formal criminal investigation into its overseas practices in May. “The SFO criminal investigation into the commercial practices of GlaxoSmithKline and its subsidiaries continues,” a spokeswoman at the SFO told Reuters in 2014.
Funnily, this event is what changed Slaoui’s course of life and made him a candidate for Trump’s Operation Warp speed. Because the scandal shook GSK’s hierarchies, with Slaoui moving from R&D to heading the vaccines branch.
Did a any of that slow the corruption machine down, did they ever stop? On 2014-15 they were also investigating other allegations that GSK paid incentives to secure sales of its products in countries including Romania, Syria, Poland, Iraq, Jordan, UAE and Lebanon.
GlaxoSmithKline PLC is investigating allegations of bribery by employees in the Middle East, according to emails reviewed by The Wall Street Journal, opening a new front for the company as it manages a separate corruption probe in China.
A person familiar with Glaxo’s Mideast operations emailed the U.K. drug company late last year and earlier this year to report what the person said were corrupt practices in Iraq, including continuing issues and alleged misconduct dating from last year and 2012″
The Guardian, April 7th 2014: “GSK looking into claims that it hired 16 Iraqi government doctors and pharmacists to improperly boost its sales Details of the allegations, which are said to have originated in 2012 but continue to this day, were sent to company executives by a whistleblower, according to the Wall Street Journal. The emails claim the alleged malpractice breaches the UK’s Bribery Act and the US Foreign Corrupt Practices Act, which ban bribery of foreign officials.”
The Guardian, April 14th 2014 “GSK acknowledged the Polish allegations dating from 2010 after an investigation by the BBC’s Panorama programme GlaxoSmithKline, the British drug company embroiled in bribery scandals in China and Iraq, has been accused of bribing doctors in Poland in the latest corruption furore to hit the business. The company, which has made a series of public promises to “root out corruption wherever it exists” following allegations that it bribed doctors with £320m worth of cash and sexual favours in China, admitted on Monday that a GSK employee was disciplined in relation to the Polish allegations. GSK, which has repeatedly trumpeted its “zero tolerance” corruption policy as it battles to salvage its corporate reputation, only acknowledged the Polish allegations – which date back to 2010-12 – after an investigation by the BBC’s Panorama programme.”
The Guardian, April 16th 2014: “GlaxoSmithKline says it is investigating bribery claims in Jordan and Lebanon Allegations say GSK sales representatives bribed doctors by issuing free samples that they were then allowed to sell on”
Reuters, August 11th 2014: “Exclusive: GlaxoSmithKline faces fresh drug bribery claims in Syria Reuters last month reported allegations of corruption in GSK’s Syrian consumer business, which sells products including toothpaste and painkillers. The consumer operation was closed in 2012 due to the worsening civil war in the country. The Syrian prescription pharmaceuticals business remains operational, however, and GSK said it was committed to supplying safe and effective drugs and vaccines to patients in need. The new corruption claims involve alleged bribes paid to boost sales of various medicines, including ones to treat cancer and to prevent blood clots.”
Reuters, July 25th, 2015: “Exclusive: GSK faces new corruption allegations, this time in Romania The latest allegations say GSK paid Romanian doctors hundreds, and in one cases thousands, of euros between 2009 and 2012 for prescribing its medicines, including prostate treatments Avodart and Duodart and Parkinson’s disease drug Requip.
According to the email, the doctors were notionally paid for speaking engagements, but in three out of six cases, including the most highly paid one, they did not give any speech. The other three medics gave only one speech each, despite receiving multiple payments. GSK also provided doctors with many international trips and made payments to them under the guise of participation in advisory boards, the email said.”
Securities and Exchange Commission, September 30, 2016 (PDF): “GlaxoSmithKline plc (“GSK”) has agreed to pay $20 million to settle charges that it violated the Foreign Corrupt Practices Act (FCPA) when its China-based subsidiaries engaged in pay-toprescribe schemes to increase sales. An SEC investigation found that the schemes spanned a period of years and involved the transfer of money, gifts, and other things of value to health care professionals, which led to millions of dollars in increased sales of GSK pharmaceutical products to China’s state health institutions. The participants included certain complicit sales and marketing managers within GSK’s Chinabased subsidiaries. GSK failed to devise and maintain a sufficient system of internal accounting controls and lacked an effective anti-corruption compliance program to detect and prevent these schemes. As a result, the improper payments were not accurately reflected in GSK’s books and records. The SEC’s order finds that GSK violated the FCPA’s internal controls and books-and-records provisions. GSK consented to the order without admitting or denying the findings, and agreed to pay a $20 million civil penalty. GSK also agreed to provide status reports to the SEC for the next two years on its remediation and implementation of anti-corruption compliance measures.”
Moncef Slaoui leaves GSK in 2017, after having brought the company on the brink of disaster, together with the Chinese division. Together with GSK’s #1 through this period, the disgraced CEO Andrew Witty, one of the darkest figures in medicine’s history, Moncef Slaoui moves to become a Pharma investor aboard Medicxi Capital, a biotechnology venture capital firm in the Philadelphia, Pennsylvania area. The rest is business as usual.
To be continued
LATER UPDATE 2, For the giggles: This is how Dork Suckerborg of Fakebook fame is doing damage control for this investigation
And this is how I do Suckerborg control. Guess what? Five minutes after I posted the thing below, Suckerborg re-instated the original post and deleted this from the group, Of course I posted it back in the comments of the original. Take your time to enjoy the multilevel beauty here, then tell me about 3d chess…
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
#FlattenTheLies Face Mask by Silview MASKS ARE BAD FOR YOU, USE THEM ONLY IF YOU HAVE NO BETTER ALTERNATIVE! OR AT PROTESTS. AND IF YOU DO, USE ONE THAT SENDS OUT THE RIGHT MESSAGE.
I’m reporting from captivity in Agadir, a Moroccan city which I’ve just found out it’s the birth-place of Moncef Slaoui, the newly appointed head of “Operation Warp Speed” , Trump’s mass-vaccination campaign. And the that’s the least disturbing thing I have to tell you. I probably need protection now, I’m warned, authorities here are not big fans of free speech, people have been arrested for much less. But this isn’t much of a life anyway; all worth it if you spread this knowledge like fire. May the public eye be my protection, if any.
US President Donald Trump selected Moroccan immunology expert Moncef Slaoui to be the head of his administration’s COVID-19 vaccine development team, working on “Operation Warp Speed.”
The Moroccan expert, 60, will serve as the US government’s “therapeutics czar” to help coordinate the development of vaccines and treatments. The role is shared between the US Department of Health and Human Services and the Department of Defense.
Slaoui will be assisted by Army Gen. Gustave Perna, the commander of United States Army Materiel Command.
Slaoui earned a Ph.D. in molecular biology and immunology from the Free University of Brussels, Belgium, and completed his postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston.
He was the former head of the vaccines division at GlaxoSmithKline (GSK), where he oversaw the development of various vaccines: Rotarix, Synflorix, and Cervarix. In 2007, he announced plans to establish a neurosciences research group in Shanghai that would employ a thousand scientists and cost $100 million; it failed miserably and ceased operations in August 2017.
In 2008, Slaoui led the $720 million acquisition of Sirtris Pharmaceuticals, which folded in 2013. In 2012, he oversaw GSK’s purchase of Human Genome Sciences for over $3 billion. In 2015 he won European approval for the world’s first malaria vaccine (Mosquirix).
When he retired from the drugmaker in 2017, GSK was still working on the vaccine for Ebola.
GSK is now working on a COVID-19 vaccine with Sanofi, the French multinational pharma giant.
“Not long after leaving GSK, the enthusiastic and outgoing Slaoui started joining biotech boards, with welcomes at SutroVax, mRNA player Moderna as well as the public outfit Intellia $NTLA, one of a handful of CRISPR/Ca9 gene editing startups dominating the field. Then, a little over a month ago, he dropped off the Intellia crew, citing a conflict but not explaining it.” – Endpoints
But his biggest business move was becoming a partner at Medicxi Capital, a biotechnology venture capital firm in the Philadelphia, Pennsylvania area.
Medicxi has built a highly experienced team and, through the scientific advisory boards (SABs) of each of its funds, has access to some of the most respected names in the pharma industry. As well as Medicxi’s senior team, now including Dr Slaoui, external members and observers on the SABs to Medicxi’s funds included (2017):
Dr Vasant (Vas) Narasimhan, Global Head of Drug Development, Chief Medical Officer and Chief Executive Officer Elect
Dr Evan Beckman, Global Head of Translational Medicine at NIBR
Nigel Sheail, Head of Business Development and Licensing
From Verily Life Sciences:
Dr Andy Conrad, Chief Executive Officer
Dr Robert Califf, Advisor and former US FDA Commissioner
Dr Patrick Vallance President, R&D
Dr Paul-Peter Tak Senior Vice President R&D Pipeline, Global Development Leader and Chief Immunology Officer
From Johnson & Johnson:
Dr. Paul Stoffels, Executive Vice President, Chief Scientific Officer
Dr. Bill Hait, Global Head, Janssen Research & Development
Dr Patrick Verheyen Global Head, Janssen Business Development
Michèle Ollier, co-founder and Partner at Medicxi, said: “Moncef has made a tremendous contribution through his role on our SABs and we look forward to his continued energetic and insightful contribution as a Partner at Medicxi. Our SAB meetings are challenging, insightful and inspiring, and contribute hugely to how we steer and advise our portfolio companies.”
Medicxi is based in London, Geneva and Jersey. The Company’s mission is to invest across the full healthcare continuum. Medicxi was established by the former Index Ventures life sciences team. Medicxi manages the legacy life science portfolio of Index Ventures as well as the new funds launched as Medicxi, Medicxi Ventures 1 (MV1) and Medicxi Growth 1 (MG1) focusing on early-stage and late-stage investments in life sciences.
GSK, Johnson & Johnson and Novartis, three of the world’s largest pharmaceutical companies back Medicxi along with Verily, an Alphabet company. These companies, whilst participating in the SABs of the funds, do not receive any preferential rights to the portfolio companies.
Medicxi’s team has been investing in life sciences for over 20 years and has backed many successful companies, including Genmab (NASDAQ Copenhagen: GEN), PanGenetics (sold to AbbVie), Molecular Partners (SWX: MOLN), XO1 (sold to Janssen) Egalet (NASDAQ: EGLT), Minerva Neurosciences (NASDAQ: NERV) and Versartis (NASDAQ: VSAR).
Since 2017, Slaoui has been also sitting on the board of Moderna, a biotechnology company also pursuing a COVID-19 vaccine, based in Cambridge, Massachusetts.
The other problem, because they always come in pairs: Trump awarded Moderna almost $0.5Billion from public money a few days before nominating Slaoui. CNN reported on May 18th:
“Valera’s efforts (Moderna subsidiary) have resulted in the demonstration of preclinical efficacy of Moderna’s mRNA-based vaccines in multiple viral disease models, Moderna said.
In the partnership with the Gates Foundation, Valera will apply its mRNA vaccine platform as well as Moderna’s drug platform Messenger RNA Therapeutics™. Designed to produces human proteins, antibodies, and entirely novel protein constructs inside patient cells, the therapeutics are secreted or active intracellularly.” – Genetic Engineering & Biotechnology News
What, you think that’s bad? What if I told you this is the last one in a very long series of collaborations between the two?
Why is no one talking about this chapter of Moncef Slaoui’s career? Well, I am:
I find most relevant this transhumanist project Slaoui worked on with Google from 2016, as reported by Bloomberg:
<<The recent partnership between GlaxoSmithKline (GSK) and Alphabet (Google) further opens the door for development in the biotechnology industry’s experimental “bioelectronics” segment. Chairman of Vaccines at GlaxoSmithKline Dr. Moncef Slaoui thinks the partnership could create an entirely new industry. “I think this is a whole new industry as big as the pharmaceutical industry … there’s a whole new world that we’re opening here which is dealing with electrical signals to connect with our biology and changes functioning,” Slaoui told CNBC’s Meg Tirrell on “Squawk Box” Monday morning. Calling Alphabet’s Verily Life Services a “really exciting partner,” Slaoui says GlaxoSmithKline shares “a very common vision of integrating electronics and big data analytics and technologies with medicines and biology.” “They bring to us the engineering capabilities, the electronics, the low power technologies and the wireless technologies that are critical to miniaturize these devices, power them and extract information from them,” Slaoui noted.>>
“GSK has been interested in this field for years, and in 2013 announced a $1 million prize for innovative bioelectronics research. In a press statement, GSK’s Moncef Slaoui said: “Many of the processes of the human body are controlled by electrical signals firing between the nervous system and the body’s organs, which may become distorted in many chronic diseases.” He said bioelectronic seeks to “correct the irregular [electrical] patterns found in disease states, using miniaturized devices attached to individual nerves.” – The Verge
And having in mind the technological terror, the transhumanist/eugenicist obsessions brought by the coronavirus policy-makers today, one quote from the same source above hits home. This whole business falls right in the arms of anyone associating the coronavirus pandemic with human microchipping. Slaoui cited animal models as the indicator that bioelectronics can treat chronic diseases with a number of different devices.
The devices themselves are very small, about “the size of a rice grain”, and can “either stimulate or black the electric signals that our brains sense through our nerves to control the functioning of our organs… The limitations are around power as power requires energy and energy means heat and heat doesn’t go well with biology.
It gets weirder
Slaoui rejected reports in late March of his involvement with a US government task force for COVID-19 vaccine development and denied as recently as May 11 any intention to work with the Trump administration. WHY?? Morocco World News reported in March 31st: “The doctor said he has no working arrangements with the US government in a statement to Moroccan French-language newspaper L’Economiste. Several local news outlets claimed that the former chairman of pharmaceutical giant GlaxoSmithKline (GSK) is part of a task force that is researching a vaccine to clamp down on the spread of the virus. The international expert is currently a member of the board of directors of American biotechnology company Moderna. Slaoui explained that he is part of the company’s research and development committee. The committee has received support from federal organizations to help fund the development of a COVID-19 vaccine. “
White House senior adviser Jared Kushner, the son-in-law of President Trump, was among the officials who interviewed Slaoui for the role.
Jared Kushner went there. Jared Kushner personally picked America’s new “Vaccine Czar” Moncef Slaoui precisely one year after the meeting. Jared Kushner is a Zionist. Jared Kushner is Trump’s son law.
To avoid a conflict of interest, Slaoui resigned from the board of the Massachusetts-based biotech firm Moderna, which had been developing a vaccine for the coronavirus. He stepped down but he didn’t give up his stakes in Moderna, as the Daily Beast reports:
“Slaoui’s ownership of 156,000 Moderna stock options, disclosed in required federal financial filings, sparked concerns about a conflict of interest. Democratic Massachusetts Senator Elizabeth Warren called Slaoui out over the matter on Twitter: “It is a huge conflict of interest for the White House’s new vaccine czar to own $10 million of stock in a company receiving government funding to develop a COVID-19 vaccine. Dr. Slaoui should divest immediately.” The company’s shares skyrocketed last month after news broke of the $483 million in federal funding to work on a coronavirus vaccine. Slaoui could not immediately be reached for comment on the matter.”
Slaoui also sits on the boards of SutroVax, the Biotechnology Innovation Organization, the International AIDS Vaccine Initiative, and the PhRMA Foundation
The Moroccan expert’s main contenders for the position of chief advisor at “Operation Warp Speed” were Algeria’s Elias Zerhouni and US’ Arthur Levinson.
Zerhouni, born in 1951, is an Algerian scientist, radiologist, and biomedical engineer. The expert has held several important positions in a number of institutions, ranging from medical schools to pharmaceutical companies and government task forces.
In 2009, under the Obama administration, Zerhouni served as the first science envoy in the US and worked towards fostering scientific and technological collaboration with other countries.
Between 2011 and 2018, as a final stage in his career, Zerhouni was the President for Global Research and Development at, well, Sanofi.
The third main candidate in the race for Trump’s COVID-19 operation, Arthur Levinson, is an American businessman specialized in biotechnology.
Levinson has served as senior advisor for several companies and institutions, including Swiss healthcare multinational Hoffmann-La Roche, Amyris Biotechnologies, the Memorial Sloan Kettering Cancer Center, the California Institute for Quantitative Biosciences, and Princeton University.
The American businessman is currently the chairman of tech giant Apple and CEO of biotechnology company Calico.
“We will get to [vaccines] eventually, but we’re not there yet. If we want to lift the lockdowns, we need to fully respect them first”
Outlook on the pandemic
During an interview on April 12, Slaoui said he expects life to begin its return to normal at the beginning of 2021 after global leaders rein in the pandemic, adding that he considers his prediction “optimistic.”
He is confident “that due to the high number of COVID-19 cases, clinical studies will reach results quickly.” He believes that “by the end of May or by early June, we will know if some of these drugs work.”
“I am very optimistic that we’ll have several vaccines for COVID-19. However, the problem is not having a vaccine. The problem is producing enough to protect eight billion people,” he continued.
Which is weird, because US Government has just announced same day spending $138mil. to turbo-boost vaccine production, and I’ve published a massive investigation piece on that.
In another interview with Moroccan television channel 2M on April 13, Slaoui forecast that the COVID-19 pandemic will heavily scar the global population.
“I believe that by 2021 our reality will not be completely back to normal but it will be improved,” he argued.
Moncef Slaoui said if the virus continues to spread, there will be no way to control it other than to create a vaccine and administer it on a massive scale.
“We will get to [vaccines] eventually, but we’re not there yet. If we want to lift the lockdowns, we need to fully respect them first,” he explained.
He said countries can phase out lockdowns when there is a proven COVID-19 treatment.
Slaoui acknowledged that there are now hundreds of clinical studies underway in many countries.
He expressed optimism that due to the increasing number of COVID-19 cases, clinical studies will achieve preliminary results quickly. “I believe that by the end of May or by early June, we will know if some of these drugs work.”
Government watchdog Public Citizen on Thursday “condemned the Trump administration’s reported appointment of a former pharmaceutical executive to the White House’s task force aimed at swiftly developing a Covid-19 vaccine as another example of the White House putting management of the pandemic in the hands of private industry. “
“If the Trump administration approaches vaccine development as it has Covid-19 prevention, testing, and treatment, the world may be in for years of more extraordinary pain,” Maybarduk added. “The dangers of global vaccine rationing are profound. No one corporation has the capacity to deliver a vaccine to all the world’s people.”
In March, Trump’s FDA came under fire for awarding monopoly status to Gilead Sciences for Remdesivir, a drug it was developing for Covid-19 treatment. The company backed off its claim after a pressure campaign led by Public Citizen.
“The U.S. government must commit to sharing clinical trial data, patents, and know-how among manufacturers and with the world, to quickly achieve the mountainous scale of production that humanity needs,” the group said.
Yes, from many reputable sources it comes out that 5G radiation can cause symptoms very similar to Covid-19’s, as many other things do. But that’s not the actual connection between 5G and Covid-19. They often appear to go hand in hand because it’s all about DATA.
From U.S. Department of Defense, Washington
Statement attributed to Lt. Col. Mike Andrews, Department of Defense spokesman: “Today (May 12th 2020) the Department of Defense and the U.S. Department of Health and Human Services, announce a $138 million contract with ApiJect Systems America for “Project Jumpstart” and “RAPID USA,” which together will dramatically expand U.S. production capability for domestically manufactured, medical-grade injection devices starting by October 2020.
Spearheaded by the DOD’s Joint Acquisition Task Force (JATF), in coordination with the HHS Office of the Assistant Secretary for Preparedness and Response, the contract will support “Jumpstart” to create a U.S.-based, high-speed supply chain for prefilled syringes beginning later this year by using well-established Blow-Fill-Seal (BFS) aseptic plastics manufacturing technology, suitable for combatting COVID-19 when a safe and proven vaccine becomes available.“
This was followed immediately by President Trump announcing he will mobilize military to distribute vaccines, when available.
ApiJect is a founding member of the Rapid Consortium. A YouTube video produced by the organization states, “These facilities will make enough prefilled syringes to inject every man, woman, and child in America with just the right dose 30 days after a vaccine becomes available. Plus every prefilled syringe can have an RFID chip attached. This will allow healthcare workers to use their mobile phones to automatically capture where and when every injection takes place, helping public health officials make more informed decisions.”
“Whether health officials are running a scheduled vaccination program or an urgent pandemic response campaign, they can make better decisions if they know when and where each injection occurs. With an optional RFID/NFC tag on each BFS prefilled syringe, ApiJect will make this possible. Before giving an injection, the healthcare worker will be able to launch a free mobile app and “tap” the prefilled syringe on their phone, capturing the NFC tag’s unique serial number, GPS location and date/time. The app then uploads the data to a government-selected cloud database. Aggregated injection data provides health administrators an evolving real-time “injection map.”
Now back to the Department of Defense statement:
“By immediately upgrading a sufficient number of existing domestic BFS facilities with installations of filling-line and technical improvements, “Jumpstart” will enable the manufacture of more than 100 million prefilled syringes for distribution across the United States by year-end 2020.
The contract also enables ApiJect Systems America to accelerate the launch of RAPID USA manufactured in new and permanent U.S.-based BFS facilities with the ultimate production goal of over 500 million prefilled syringes (doses) in 2021. This effort will be executed initially in Connecticut, South Carolina and Illinois, with potential expansion to other U.S.-based locations. RAPID will provide increased lifesaving capability against future national health emergencies that require population-scale vaccine administration on an urgent basis.
RAPID’s permanent fill-finish production capability will help significantly decrease the United States’ dependence on offshore supply chains and its reliance on older technologies with much longer production lead times. These supplies can be used if a successful SARS-COV-2 vaccine is oral or intranasal rather than injectable.”
ApiJect Systems America, Inc., a public benefit corporation based here, today announced that it has been awarded an HHS-DOD Title 3, DPA contract valued up to $138 million to accelerate the building of a new U.S.-based, high-speed, population-scale emergency drug injection capability with prefilled syringes from its subsidiary RAPID USA Inc. RAPID USA’s emergency program, “Project Jumpstart” is being initiated to supply 100 million prefilled syringes by year-end.
RAPID USA’s Project Jumpstart will immediately contract with a sufficient number of existing U.S.- based Blow-Fill-Seal (BFS) facilities to install filling lines and technical upgrades to enable production of prefilled syringes before year-end. BFS is a well-established high-speed medical- grade plastics aseptic manufacturing process that specializes in the high-volume production of pharmaceutical products. Jumpstart will also purchase and stockpile 100 million Needle Hubs for ApiJect prefilled syringes. Jumpstart will develop the capability to manufacture a minimum of 30 million prefilled syringes per month once therapeutic drugs and vaccines become available.
In parallel with Project Jumpstart, RAPID USA will build a network of 30 U.S.-based BFS manufacturing lines at three different, geographically dispersed, sites. Once operational, these 30 lines will fill, finish, and package up to 330 million prefilled BFS syringes per month. Initial production will begin in late 2021. RAPID USA will also build a U.S.-based training and prototyping facility capable of supporting 500 U.S.-based jobs at RAPID USA’s three manufacturing sites.
ApiJect Systems America CEO Jay Walker commented: “ApiJect’s Title 3, DPA funding gives our subsidiary RAPID USA the capability to swiftly create the domestic surge capacity in prefilled syringes that will be needed as therapeutics and vaccines become available. Project Jumpstart is the first stage in RAPID’s HHS-DOD supported two-stage effort. Within six months, Project Jumpstart will create a surge capacity to supply 100 million prefilled syringes and more than 500 million in 2021. Stage two, running in parallel with Jumpstart, will have RAPID USA building a network of 30 U.S.-based BFS manufacturing lines, enabling a monthly production of up to 330 million BFS prefilled syringes.”
Walker continued: “When discussions with HHS ASPR first began last year ApiJect was then focused on global health, specifically injection safety in low and middle-income countries where needle reuse and contaminated multi-dose vials kill as many as two million people every year and infect 10 million or more with transmissible diseases such as HIV and Hep-C. ASPR’s leadership wanted us to turn our attention to building a U.S.-based population-scale surge capacity for flexible biodefense purposes. We started immediately, and when COVID-19 emerged as a pandemic threat, our public-private partnership with HHS, which had been created in January, accelerated to focus on building both an emergency capability as well as longer-term sustainable injection surge capacity.”
Walker further commented: “RAPID USA is led by our multi-disciplinary team of experienced engineers, pharmaceutical technology experts, and management leadership. Our team is expending extraordinary efforts to ensure that when drugs are developed and tested all Americans can receive critical injections. We will have done our part by providing the manufacturing capacity to support the necessary volume of ready-to-use prefilled syringes that contain essential medicines, be they therapeutics or vaccines. Our public-private partnership, supported by Jefferies Financial Group, and the HHS-DOD Title 3 contract, demonstrates the vital role that RAPID will play in the war against COVID-19, as well as future national health emergencies.”
Rich Handler, CEO and Brian Friedman, President of Jefferies Financial Group, Inc., commented: “Finding a solution to the COVID-19 crisis demands the best from each of us, as companies and as individual citizens. When we learned what ApiJect was doing with the U.S. Government, Health and Human Services and the Department of Defense, we saw a role where Jefferies and our nearly 4,000 global professionals could make a difference. We invested in RAPID USA as we believe it is the right step at the right time, and we will continue to support ApiJect to assure RAPID USA can do their important job of building the surge capacity needed here on U.S. soil to help put this crisis behind us.”
#FlattenTheLies Face Mask by Silview MASKS ARE BAD FOR YOU, USE THEM ONLY IF YOU HAVE NO BETTER ALTERNATIVE! OR AT PROTESTS. AND IF YOU DO, USE ONE THAT SENDS OUT THE RIGHT MESSAGE.
ABOUT APIJECT AND RAPID USA
ApiJect Systems America, Inc., is a public benefit corporation dedicated to making injectable medicines safe and available for everyone. By building a network using high-speed, high-volume Blow-Fill-Seal medical grade plastics technology and an interlocking Needle Hub, ApiJect can supply hundreds of millions of ultra-low-cost prefilled syringes with optional RFID tags to enable GPS-based mobile tracking. ApiJect, along with the U.S. Department of Health and Human Services, is a founding member of the RAPID Consortium, a public-private partnership dedicated to giving the U.S. and the world the surge drug packaging it needs for addressing future pandemics and bio-emergencies. Learn more about ApiJect at www.apiject.com.
RAPID USA, Inc., a subsidiary of ApiJect Systems America, Inc., is building and will manage the high-speed, high volume surge capacity for drug fill, finish and packaging that America needs to effectively respond to future pandemics and bio-emergencies. Starting in the second half of 2021, RAPID USA will begin rolling out new U.S.-based BFS drug packaging lines that once completed in 2022, will provide the capacity to fill and finish up to 330 million prefilled syringes per month for the U.S. and the world. The HHS-DOD emergency program, Project Jumpstart, to supply the U.S. with 100 million BFS prefilled syringes by year-end, is a RAPID USA initiative. Learn more at www.rapidconsortium.com.
The inventor of ApiJect, the first BFS injection device, is Marc Koska, one of the world’s most respected and successful social entrepreneurs. “At 23 years of age, Marc Koska was living an idyllic lifestyle as a self-confessed beach bum’, sailing yachts around the Caribbean and generally having a good time. And although he had always thought he was destined to do something big, it took a trip back to the UK in 1984 to tell him what that something would be.
“I saw an article in The Guardian predicting the transmission of HIV through the re-use of syringes. And I thought, that’s what I’ve been waiting for!” Doctors were re-using syringes, and people were being infected with wholly preventable diseases by people in which they had enormous faith. “It was a nightmare situation.” So there and then he designed and put together a disposable syringe, which would automatically disable after its first use. Fast-forward 17 years from that seminal moment in May 1984, and Koska sold his first syringe after which there was no stopping him: he’s since sold 700 million.
But it wasn’t easy. The big manufacturers didn’t want it to progress, he says, and the World Health Organisation in Geneva weren’t much help either. They ignored the 23-year-old “dipstick” with a vision of a safe injection policy. Did they even say they liked the idea? “I don’t know, they told me to bugger off!” he chuckles. He doesn’t believe the market was ready for the product back then; as he says, he had to remove 100 bricks from his path to get to the stage today where his company, Star Syringe, is the biggest Auto Disable (AD) syringe manufacturer in the world.” – Money Week, 2006
In 2005, MARC founded the SafePoint Trust charity NGO “to educate children about the dangers of employing used needles.” Kept living from little fundings, presentations and mainly trying to hit the jackpot selling vials.
In 2015, Chinese WHO director, Dr. Margaret Chan announced a new global policy on injection safety, promoting auto-disable-syringes and Marc’s set for life. The K-1 is now licensed and manufactured by 14 global manufacturers. His biography gets a glorious “upgrade” in the Guardian, he was no more a former “beach bum”, actually in 1984, he “was working in the Caribbean, building forensic models to support murder cases,”
Among many other honors bestowed on Mr. Koska, he was made an Officer of the Order of the British Empire for his “contribution to global healthcare”. From a “beach bum” to royal honors.
All sponsored by Bill Gates and US Government, the top donors to WHO’s budget.
Din any red light blink when I mentioned Marc Koska’s benefactor, “Chinese WHO director, Dr. Margaret Chan”? Yes friends, the wife of the Ministry of Foreign Affairs of the People’s Republic of China, Dr. David Chan was running WHO at the time and relaunching Marc’s career, after many years in which they ignored his intense lobbying. Should it be because of a little improvement added to the product design – the RFID chip?
A few words on Jay Walker, who leads ApiJect’s technology efforts, as well as its business and commercialization activities. He is best known as the founder of Priceline and curator of TEDMED. Yes, TED is ran by Pharma suits too, Bill Gates funded them and one more of their guys is in Apiject, alongside a former GlaxoSmithKlein executive and other Pharma troopers, according to their own website, already linked above. So, of course, TED platformed this business and you can find Koska speaking there in 2010.
A serial entrepreneur, Mr. Walker has founded three companies that have gone from launch to 50 million customers each. Mr. Walker is the world’s 10th most patented inventor, with more than 750 issued U.S. patents in technology-related fields.
Active in the field of medicine since 2012, Mr. Walker serves as chairman and curator of TEDMED, the health and medicine edition of the world-famous TED Conference. He is also Chairman of Upside, a travel and technology company that serves the unmanaged business traveler. A passionate student and practitioner of imagination, Mr. Walker founded and curated the Library of the History of Human Imagination, which Wired Magazine called, “the most amazing private library in the world.”
Bottom line: All the data collected by these RFID’s, the thermal scanning drones, the tracking, all the technological carnival around coronavirus and vaccines seems to be the actual agenda, not health, and it all needs 5G. This vaccination campaign proves to be more about data, surveillance and control, so 5G has to follow with it. US and China may fight on TV, but have collaborated on this at least since the times Fauci was funding Wuhan labs with American taxpayer money. They may have different propaganda shows on TV, but on the field US follows China’s footsteps with Chinese collaboration and know-how. WHO offered the “Umbrella Corporation” under which apparent enemies could collaborate for common population and resources control agendas.